FDA Expands ADMA's IVIG Label to Include Pediatric Patients With Primary Immunodeficiency

The FDA has approved a supplemental biologics license application for immune globulin intravenous (IVIG, human-slra; ASCENIV; ADMA Biologics), expanding its indication to include pediatric patients 2 years and older with primary humoral immunodeficiency (PI). The therapy was previously approved for use in patients 12 years and older.¹

“This expanded label for Asceniv allows ADMA to actively address the treatment needs of younger PI and immunocompromised patients earlier in their treatment journey,” Adam Grossman, president and CEO of ADMA, said in a news release. “In the periods ahead, we look forward to continuing to expand the utilization of Asceniv by offering our differentiated and patented immune globulin as an FDA-approved treatment option for immunocompromised pediatric patients in need.”¹

IVIG is a plasma-derived product indicated for the treatment of primary immunodeficiency diseases.² It is manufactured using a proprietary plasma pooling process that incorporates respiratory syncytial virus (RSV)–enriched donor plasma, designed to provide elevated titers of antibodies against respiratory pathogens.³

Pediatric Label Expansion and Regulatory Context

The approval fulfills a postmarketing requirement to evaluate IVIG in pediatric populations. The submission included data from a pediatric assessment program conducted following the product’s initial approval in 2019.^1,4

With this update, the prescribing information has been revised to allow use in children as young as 2 years, aligning IVIG with other therapies that have expanded into pediatric populations.¹ Earlier access to therapy is particularly important for pediatric patients with PI, who face increased risks of recurrent infections, hospitalization, and long-term complications.⁴

Company representatives noted that expanding treatment into younger populations may help clinicians intervene earlier in disease progression. In the announcement, ADMA stated that the approval “enables physicians to treat pediatric patients sooner, potentially improving clinical outcomes and reducing the burden of disease.”¹

Clinical and Treatment Implications

PI disorders are characterized by impaired antibody production, leaving patients vulnerable to recurrent bacterial and viral infections. IVIG therapy remains a cornerstone of treatment, providing passive immunity through pooled IgG antibodies derived from human plasma.²

The expanded indication for IVIG offers an additional treatment option for pediatric patients requiring immunoglobulin replacement, particularly those with persistent or severe infections. Earlier initiation of therapy may improve infection control and overall quality of life, although long-term real-world outcomes will continue to be evaluated.³

Notably, the product’s RSV-enriched plasma composition may provide broader pathogen coverage compared with conventional IVIG therapies.³ This characteristic may be particularly relevant in pediatric populations, where respiratory infections remain a leading cause of morbidity.

Broader Market and Development Context

The approval also strengthens ADMA Biologics’ immunoglobulin portfolio and builds on prior pediatric-focused regulatory efforts. Expanding access to younger patients may increase utilization in specialty immunology and pediatric care settings.

From a regulatory standpoint, the decision reflects the FDA’s continued emphasis on ensuring that biologic therapies are evaluated across age groups, particularly for chronic conditions such as primary immunodeficiency, which often present early in life.

Conclusion

The FDA’s expansion of IVIG to include pediatric patients 2 years and older represents an important advancement in the management of primary immunodeficiency. By enabling earlier intervention, this approval may help reduce infection burden and improve outcomes in a vulnerable patient population while reinforcing the role of IVIG therapy in comprehensive immunologic care.

REFERENCES

1. ADMA Biologics announces FDA approval to expand the label for Asceniv to include pediatric immunocompromised patients two years of age and older. News release. Adma Biologics. May 4, 2026. Accessed May 4, 2026. https://ir.admabiologics.com/news-releases/news-release-details/adma-biologics-announces-fda-approval-expand-label-ascenivtm

2. Asceniv. FDA. Updated May 4, 2026. Accessed May 4, 2026. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/asceniv

3. Asceniv (immune globulin intravenous, human-slra). ADMA Biologics Inc. Accessed May 4, 2026. https://www.asceniv.com/

4. FDA approves novel intravenous immune globulin. Pharmacy Times. April 2, 2019. Accessed May 4, 2026. https://www.pharmacytimes.com/view/fda-approves-novel-intravenous-immune-globulin